Publications by authors named "Toby A Eyre"

Claim this Profile
E
Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
Lin Wang, Murat Kurt, Tim Disher, Fei Fei Liu, Samantha Craigie, Toby A Eyre

Leuk Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.
Georg Heß, Toby A Eyre, Min-Hua Jen, Jiewen Zhang, Benjamin Goebel

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
David J Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Toby A Eyre

Lancet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, Helen Won, Shady I Tantawy, Toby A Eyre

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
Mats Jerkeman, Igor Aurer, Elias Campo, Chan Y Cheah, Jonathan Clark, Toby A Eyre

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CART in MCL: risk and reward?
Toby A Eyre

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Nitin Jain, Toby A Eyre, Katherine B Winfree, Naleen Raj Bhandari, Manoj Khanal

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Adam S Kittai, Monia Marchetti, Othman Al-Sawaf, Ohad Benjamini, Alexey V Danilov, Toby A Eyre

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
Toby A Eyre, Chan Y Cheah, Clémentine Sarkozy, Anita Kumar, Steven Le Gouill

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review.
Aisling Barrett, Callum Harris, Toby A Eyre

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
Sridhar Chaganti, Christopher P Fox, Bernard D Maybury, Cathy Burton, Sally F Barrington, Toby A Eyre

Br J Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
Jonathan A Cook, Piers E M Patten, Nicholas Peckham, Paul Moss, Neil Phillips, Toby A Eyre

Lancet Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.
Lindsey E Roeker, Catherine C Coombs, Nirav N Shah, Wojciech Jurczak, Jennifer A Woyach, Toby A Eyre

Acta Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, Toby A Eyre

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper.
Matthew R Wilson, Kate Cwynarski, Toby A Eyre, Jeffery Smith, Sridhar Chaganti

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Toby A Eyre

Lancet Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni, Andrea Bernardelli, Ingrid Glimelius, Massimo Mirandola, Karin E Smedby, Toby A Eyre

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Yeong Jer Lim, Victoria Ward, Anthony Brown, Eloise Phillips, Barbara Kronsteiner, Toby A Eyre, David W Eyre

Br J Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
Matthew S Davids, Jeff P Sharman, Paolo Ghia, Jennifer A Woyach, Toby A Eyre

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
Christopher P Fox, Sridhar Chaganti, Graham McIlroy, Sally F Barrington, Cathy Burton, Toby A Eyre

Br J Haematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Ann Tivey, Rohan Shotton, Toby A Eyre, David Lewis, Louise Stanton

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Toby A Eyre

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report.
Aisling Barrett, Toby A Eyre, Shaheel Bhuva, Mahmoud Aljurf, Riad El Fakih

EJHaem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Talha Munir, David A Cairns, Adrian Bloor, David Allsup, Kate Cwynarski, Toby A Eyre

N Engl J Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis